It’s ironic that PFE didn’t do either the acquisition of Knoll or the Humira co-promotion sought by ABT because PFE was so heavily committed to the success of Bextra, which was subsequently withdrawn from the market.
Good blog by LaMattina. The Timmerman article LaMattina refers to was posted in #msg-74453479.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.